RECOMMENDATION(S):
Approve and Authorize the Purchasing Agent, on behalf of the Health Services Department, to execute a Purchase Order with Roche Diagnostics Corp., in an amount not to exceed $790,148 for purchase of reagents and supplies for the Contra Costa Regional Medical Center (CCRMC) for the period of May 1, 2017 through April 30, 2022.
FISCAL IMPACT:
100% funding is included in the Hospital Enterprises Fund I budget.
BACKGROUND:
CCRMC uses the Surepath Pap Smear for its patients. Roche Diagnostics Corp. has the only Food and Drug Administration approved Human papillomavirus (HPV) test on Surepath medium. One single specimen vial can perform both HPV and pap-test. The HPV test is able to detect a total of 14 HPV high risk types.
CONSEQUENCE OF NEGATIVE ACTION:
If this purchase order is not approved, the Pathology department will not be able to efficiently and effectively detect cervical cancer in women since the HPV test with the pap together is the only screening test for this cancer.
|